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Clinical trials have demonstrated positive proof of eﬃcacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in
both anxiety and schizophrenia. Importantly, evidence suggests that these drugs may also be neuroprotective against glutamate
excitotoxicity, implicated in the pathogenesis of Parkinson’s disease (PD). However, whether this neuroprotection also translates
into functional recovery is unclear. In the current study, we examined the neuroprotective eﬃcacy of the dual mGluR2/3 agonist,
2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC), and whether this is accompanied by behavioral recovery in a rodent
6-hydroxydopamine (6-OHDA) model of PD. We now report that delayed post lesion treatment with 2R,4R-APDC (10 nmol),
results in robust neuroprotection of the nigrostriatal system, which translated into functional recovery as measured by improved
forelimb use asymmetry and reduced (+)-amphetamine-induced rotation compared to vehicle treated animals. Interestingly, these
beneficial eﬀects were associated with a decrease in microglial markers in the SNc, which may suggest an antiinflammatory action
of this drug.
1. Introduction
Dopamine replacement therapy provides eﬀective relief of
motor symptoms in PD patients, but has no proven eﬀect
on the degeneration of the nigrostriatal system [1, 2].
Pathophysiological evidence suggests that neurodegenera-
tion in PD has an excitotoxic component, mediated through
hyperactivity of glutamatergic subthalamic nucleus (STN)
output pathways as a consequence of striatal dopamine
(DA) depletion [3]. Owing to their diﬀerential expression
and neuromodulatory role in glutamate neurotransmission
in the basal ganglia, metabotropic glutamate receptors
(mGluR) may represent promising drug targets for PD
pharmacotherapy [4, 5]. Theoretically, mGluR are perceived
to be advantageous due to the lack of adverse eﬀects that
are induced by ionotropic receptor antagonists [6]. This
is borne out by recent positive proof of eﬃcacy of Group
II mGluR (comprising mGluR2 and mGluR3 subtypes)
agonists in clinical trials of both schizophrenia [7] and
generalized anxiety disorder [8], in which these drugs were
well tolerated with minimal extrapyramidal side eﬀects.
Interestingly, group II mGluR are considered promising
drug targets for “neuroprotective receptors”, since their
activation inhibits glutamate release at key synapses in the
basal ganglia, including subthalamonigral synapses that are
overactive as a result of striatal DA depletion in PD [9–11].
Further, activation of mGluR2/3 stimulates the production
and release of neurotrophic factors from glial cells in vitro
[12, 13] and in vivo [14–16]. Results from our laboratory
and others reveal a moderate neuroprotective eﬀect of Group
II mGluR agonists in rodent models of PD, the magnitude
of which was dependent on lesion severity [14, 17–19].
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Nevertheless, it remains unclear whether these neuroprotec-
tive eﬀects also translate eﬀectively into functional recovery
in vivo. Indeed, systemic administration of selective dual
mGluR2/3 agonists reverses reserpine-induced akinesia, but
not rotational asymmetry following amphetamine challenge
in vivo, despite concomitant, albeit weak, neuroprotection of
the nigrostriatal system [18]. By contrast, other studies have
reported reversal of both haloperidol-induced muscle rigid-
ity and catalepsy in rats following Group II mGluR agonist
treatment [9, 20]. On the other hand, intrastriatal injection
of the dual mGluR2/3 agonist 2R,4R-4-aminopyrrolidine-
2,4-dicarboxylate (2R,4R-APDC) had no eﬀect in these
behavioural tests [21]. Interestingly, intranigral injection
of the nonselective mGluR2/3 agonist DCG-IV alleviated
reserpine-induced akinesia in rodents [22]. However, this
compound is not selective for mGluR2/3 receptors alone and
thus is not appropriate for use with in vivo models [23].
Taken together, pharmacotherapy targeting Group II
mGluR in the basal ganglia appears to oﬀer the potential
to combine both symptomatic improvements with potential
neuroprotection of remaining nigral neurons [4, 5]. Nev-
ertheless, there seems to be conflicting data in the extant
literature regarding both the degree of neuroprotection and
the behavioural eﬀects of dual mGluR2/3 treatment in vivo
in animal models of PD, which may in part be related to the
diﬀering routes of administration employed in each study.
Thus, our goal in the current study was to extend our initial
findings with the Group II mGluR agonist 2R,4R-APDC to
address this question in a rodent partial lesion model of
PD. In addition, taking into account the published eﬀects of
Group II mGluR activation on glial cells, we have examined
inflammatory markers, alongside markers of neuronal loss
in the nigra to determine whether intranigral treatment with
2R,4R-APDC also influences inflammatory changes in vivo.
2. Experimental Procedures
2.1. Materials. 2R,4R-APDC was obtained from Tocris
Cookson Bioscience (Bristol, UK). All other reagents and
compounds were obtained from Sigma-Aldrich Ltd. (Poole,
UK) unless stated otherwise in the text.
2.2. Experimental Animals. Male Sprague-Dawley rats (250
± 20 g; Harlan UK Ltd., Bicester, UK) were housed in groups
of three at 21±1◦C on a 12-hour light : dark cycle (lights on
07:00 h , lights oﬀ 19:00 h). Standard rat chow and drinking
water were available ad libitum throughout the study. All
animal experiments were carried out in accordance with the
guidelines published in the Home Oﬃce Animals (Scientific
Procedures) Act, UK, 1986 under project license number PIL
70/6486, with local ethical approval (Ethical Committee of
Imperial College, London).
2.3. Stereotaxic Implantation of Guide Cannulae. Rats were
anaesthetized with a mixture of isoflurane (5% for induction,
1%–3% for maintenance, flow rate 1 L/min) in medical
air/oxygen mixture (70/30%) and placed in a stereotaxic
frame (David Kopf instruments, Tujunga, USA), with the
incisor bar set at 3.3 mm above the interaural line [24].
Body temperature was monitored using a rectal probe and
maintained at 37◦C during surgery using a thermostatically
controlled heated mat. Stainless steel guide cannulae (26-
gauge, Plastics One, Roanoke, VA, USA) were unilaterally
implanted 1 mm above the left SNc at the following coordi-
nates; AP: −3.0 mm and ML: +2.5 mm (relative to bregma),
DV: −7.6 mm (relative to dura; Paxinos and Watson, 1986)
as described previously [19]. Postsurgery, rats were placed in
a heated recovery chamber to recover from the anaesthetic.
Postoperative care included individual caging, analgesia
(buprenorphine, 0.3 mg/kg s.c during the first 48 hours),
fluid replacement (4 mL 0.18% glucosaline solution i.p),
and mashed high-nutrient food pellets during the first week
after surgery. Animals were checked daily for signs of gross
neurological or behavioural abnormalities and weighed to
monitor recovery. No experimental interventions were made
until animals had completed a minimum 10-day recovery
period.
2.4. Experimental Design. Following recovery from surgery,
cannulated animals were randomly assigned to drug (n = 8)
or vehicle treatment groups (n = 10). To investigate the eﬀects
of delayed 2R,4R-APDC-treatment on neuroprotection, 6-
OHDA lesioned animals received intranigral injections of
10 nmol 2R,4R-APDC or drug vehicle, once daily, for seven
consecutive days as per our previously published protocol
[19] with the exception that drug treatment was delayed
until 48 hours post lesion. To evaluate whether 2R,4R-
APDC improved the behavior of 6-OHDA lesioned animals,
both treated and control animals were assessed for their
performance in the spontaneous forelimb test and the degree
of contralateral rotation following amphetamine injection.
Performance in the forelimb asymmetry test was assessed
prior to lesioning and drug treatment to establish a baseline
and control for the eﬀects of cannulae implantation on
behavior. Animals were retested for performance in this
test upon completion of drug treatment (7 days), equiv-
alent to 9 days post lesioning. Animals were assessed for
amphetamine-induced rotational behavior 24 hours later.
In both treatment groups, neuroprotection was quantified
by postmortem immunohistochemical analysis of tyrosine
hydroxylase (TH)-positive cells in the substantia nigra pars
compacta (SNpc) and biochemical measurement of strital
monoamine concentrations by HPLC. In addition neuronal
cell counts were performed in the SNc to control for
changes in TH expression in atrophic neurons. Lastly, the
eﬀects of 6-OHDA lesioning and drug or vehicle treatment
on inflammatory markers were assessed using postmortem
immunohistochemistry for astroglial and microglial cell
markers, respectively. Details of 6-OHDA lesioning, drug
preparation and administration, behavioral testing, and
postmortem immunohistochemical, and biochemical anal-
yses are provided in the sections below.
2.5. Induction of 6-OHDA Nigrostriatal Lesions. Unilateral
6-OHDA nigrostriatal lesions were created as previously
described elsewhere [25]. Briefly, 12 μg 6-hydroxydopmine
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hydrobromide (6-OHDA, free base, Sigma-Aldrich Ltd.
Poole, UK) in 4 μL 0.1% ascorbic acid/saline solution was
infused into the left SNc using a 26-gauge stainless steel
injection cannulae, extending 1 mm below the tip of the
indwelling guide cannula, attached with flexible tubing
(Portex, Hythe, UK) to a 10 μL 700 series Hamilton syringe
mounted on a motorised Harvard micropump (Harvard
Apparatus, Edenbridge, UK). Infusions were made at a rate
of 1 μL/min followed by a 5-minute equilibration time,
during which the needle remained in place and was then
slowly retracted.
2.6. Drug Preparation and Intranigral Administration. Stock
solutions of 2R,4R-APDC were prepared in phosphate
buﬀered saline (PBS; mM: NaCl 137; KCl 2.7; KH2PO4 1.8;
Na2HPO4 10) and adjusted to pH 7.4. Drug concentrations
were selected based on published in vitro EC50 and Ki
values for each compound at mGluR2/3 [23, 26] and on
our previous experience with this compound [19] to avoid
confounding eﬀects due to activation of other mGluR sub-
types. 2R,4R-APDC was chosen for use as it retains selectivity
for mGluR2/3 even at relatively high concentrations [26].
Drugs were aliquoted and stored at −80◦C according to the
manufacturer’s instructions. Fresh drug aliquots were used
on each day of drug administration to avoid repeated freeze-
thaw cycles. In all treatment groups, unilateral intranigral
drug injections were performed exactly as described for
6-OHDA lesions, in a final injection volume of 4 μL.
Importantly, in our previous study with this compound [19],
drug treatment was initiated one hour prior to 6-OHDA
lesioning, which whilst providing robust proof-of-concept,
is not ideal. To address this limitation, in the current study
drug treatment initiation was delayed until 48 hours post
lesion, at which point nigrostriatal degeneration should be
ongoing in vivo. In all groups, drug or vehicle treatment
was initiated 48 hours post 6-OHDA lesioning. Intranigral
injections were performed once daily, at the same time,
over 7 consecutive days. Following all intranigral injections,
animals were observed qualitatively over a period of 20
minutes for any signs of gross behavioral abnormalities in
response to the drug injection.
2.7. Assessment of Spontaneous Forelimb Use and Rotational
Asymmetry Following (+)-Amphetamine Challenge. Perfor-
mance in the spontaneous exploratory forelimb use test
was assessed as previously described by others [27, 28]. In
brief, animals were placed in a clear plastic cylinder (height:
30 cm, width: 20 cm) and forelimb use asymmetry was
assessed during rearing behaviour [27]. Forelimb contact
with the cylinder wall was scored as left, right, or both and
the percentage forelimb asymmetry was determined using
the following formula: ((contralateral limb placements −
ipsilateral limb placements)/total placements) × 100) [27].
As described above, forelimb asymmetry was assessed 10
days after cannulation and 1 day prior to 6-OHDA lesioning.
Animals were then retested prior to sacrifice, following 7 days
of drug treatment, equivalent to 9 days post lesion, by an
investigator blinded to the treatment group.
Rotational asymmetry was assessed 24 hours after com-
pletion of drug treatment, equivalent to 10 days post lesion.
Animals were administered amphetamine (5 mg/kg i.p.) to
induce rotational behavior as described previously [29].
Animals were placed in a clear circular test arena (25 ×
15 cm) and following a short period of acclimatization
(30 minutes), injected with the dopaminergic agonist. The
complete number of contralateral and ipsilateral turns was
then recorded for 60 minutes postinjection.
2.8. Tissue Preparation. Upon completion of behavioral
testing, 9 days after the initial drug injection and 11 days post
lesion, animals were sacrificed by decapitation and the brains
quickly dissected out onto a chilled platform and cut at the
level of the infundibular stem (−4.16 mm from bregma) to
produce a fore- and hindbrain block containing the corpus
striatum and SNc, respectively. Hindbrain blocks were fixed
in 4% paraformaldehyde for 5 days, cryoprotected in 30%
sucrose for 24–48 hours and stored desiccated at−80◦C until
cryostat sectioning. Coronal sections (20 μm-thick) were
cut on a cryostat, (Bright Instruments, Cambridge, UK),
throughout the rostral to caudal extent of the SNc (−4.80
to 6.30 mm from bregma; Paxinos and Watson, 1986). Free-
floating sections were collected in series and stored in PBS
(pH 7.4) containing 0.05% sodium azide as a preservative
until immunostaining. From the forebrain blocks, the left
and right striata were quickly dissected out, snap-frozen, and
stored at −80◦C until biochemical analysis of monoamine
content.
2.9. Immunohistochemistry. Immunohistochemistry was
performed using a standard immunoperoxidase method as
previously described [25]. Briefly, free-floating sections
were washed in PBS (pH 7.4, 3 × 5 minutes) and
endogenous peroxidase activity quenched by incubation
in 1% hydrogen peroxide solution (30 minutes) followed
by cell permeabilisation in PBS containing 0.1% triton
X-100 (15 minutes). Nonspecific biding was blocked by
incubating sections in 3% normal goat serum (NGS, MP
Biomedicals, Eschwage, Germany) diluted in PBS for 1
hour. Sections were incubated with primary antibody
diluted in PBS containing 0.1% triton and 3% NGS for
18 hours at room temperature. Dopaminergic neurons
were identified using rabbit antirat tyrosine hydroxylase
(TH, AB151, Chemicon Europe, Watford, UK, 1 : 3000)
with adjacent sections probed with mouse antirat neuron
specific nuclear protein (NeuN, MAB377, Chemicon Europe,
1 : 2000;) to control for changes in TH protein expression.
Astrocytes were identified using rabbit antirat glial fibrillary
acidic protein (GFAP, AB5804, Chemicon Europe, 1 : 400),
and two antibodies, mouse antirat cd11b (clone OX-42;
CBL1512, Chemicon, Europe, 1 : 400) and mouse antirat
major histocompatibility complex (MHC) class II (clone
OX6; ABD Serotec, Kidlington, UK) were used to identify
microglia and activated microglia, respectively, since it
has been reported that activated microglia express high
levels of MHC class II [30]. After treatment with primary
antibodies, sections were incubated with biotinylated
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secondary antibody (goat α-rabbit or α-mouse IgG, Vector
Labs, Peterborough, UK) diluted 1 : 200 in PBS for 2
hours. Sections were incubated for a further 1 hour in
horseradish peroxidase conjugate (Vectastain Elite ABC Kit,
Vector Labs, Peterborough, UK), and antibody binding was
visualised using a 3′3-diaminobenzidine (DAB) peroxidase
staining kit with nickel enhancement (DAB peroxidase kit
SK-4100, Vector Labs, Peterborough, UK) according to
the manufacturer’s instructions, followed by washing in
distilled water. Each step was preceded by washing in PBS
(pH 7.4, 3 × 5 minutes). Free-floating immunostained
sections were mounted onto poly-L-lysine-coated slides
(VWR, Lutterworth, UK) and allowed to adhere by air-
drying. Mounted sections were rinsed with tap water before
dehydration through a series of graded alcohol and xylene
solutions, prior to application of coverslips using DPX
mounting medium. Negative controls were performed in
which the primary antibody was omitted and in which
no immunostaining was observed, thereby confirming the
specificity of the primary antibodies.
2.10. Cell Counting. The total number of TH-positive cells
were counted manually rostro-caudally through the SNc in
contiguous sections using a Nikon Eclipse E800 microscope
(Nikon, Tokyo, Japan) connected to a JVC analogue camera
and Image Pro Plus software (Media Cybernetics, Finchamp-
stead, UK). The SNc was outlined using a manually traced
region of interest (ROI) at low magnification (×4). The
number of TH positive cells was counted in the contralateral
and ipsilateral hemispheres at the level of third cranial nerve,
within a 100 μm × 100 μm counting area at high magnifi-
cation (×40) only within this defined ROI. Importantly, the
level of the third cranial nerve provides a robust anatomical
landmark where the SNc can be reliably delineated from
the VTA, as previously described [31, 32]. Lesion size was
then calculated as a percentage of the unlesioned contralat-
eral hemisphere. Although not a stereological procedure,
previous studies have shown that the 3rd nerve rootlets
provide a reliable anatomical landmark at which the extent
of cell loss is reflective of cell loss throughout the entire
substantia nigra [32]. Further, manual cell counts assessed
at the level of the third cranial nerve have been demonstrated
to give equivalent results, not significantly diﬀerent to that
obtained from unbiased stereological estimates at the same
level using an optical fractionator probe design [31]. These
data strongly suggest that manual cell counting at the level
of the third nerve is a viable method of determining cell loss
and neuroprotection in this model [31].
To control for changes in TH expression in atrophic
neurons, NeuN+ cell bodies in the SNc were counted in
exactly the same manner as described above with reference
to adjacent TH-immunostained sections from the same
animal. Two operators blinded to the treatment group
under analysis performed all quantitative cell counting (H.C.
and H.P.). At the same time as quantitative analysis was
performed, representative photomicrographs were captured
at×40 magnification using the same microscope and camera
set-up and Image Pro Plus v.5.0 image analysis software
(Media Cybernetics, Finchampstead, UK).
2.11. Measurement of Striatal Monoamines Using HPLC-ECD.
Striatal monoamine content was analysed using HPLC-ECD,
as previously described [19]. Briefly, the left and right striata
were thawed, weighed and homogenised in 500 μl of ice-cold
homogenisation buﬀer (50 mM trichloroacetic acid, 0.5 mM
EDTA) containing 0.5 pmol/mL 3,4-dihydroxybenzylamine
hydrobromide (DHBA) as an internal standard. Striata were
homogenised for 20 seconds by sonication (Soniprep, Sanyo,
Loughborough, UK) and placed on ice for 10 minutes
to allow complete extraction of monoamines, followed by
centrifugation at 13000 g at 4◦C for 10 minutes (Heraeus
Centrifuges, Newport Pagnell, UK). Sample supernatant
was filtered (0.2 μm PTFE filter, Whatman, Maidstone, UK)
into HPLC vials (Chromacol, UK) and loaded onto an
autosampler (Gina 50, Dionex, Camberley, UK) maintained
at 5◦C. From each sample, 20 μL were injected and analysed
for dopamine (DA), dihydroxyphenylacetic acid (DOPAC),
and homovanillic acid (HVA) content using a phosphate
buﬀer mobile phase (0.1 mM KH2PO4, 0.1 mM EDTA, and
1 mM octyl sodium sulphonate, 10% methanol V/V, adjusted
to pH 2.5 with orthophosphoric acid) at a flow rate of
0.9 mL/min on an Altex Ultrasphere 3 μm ODS column
(4.6 mm × 7.5 cm, Beckman-Coulter, High Wycombe, UK).
Samples were quantified by an electrochemical analytical cell
(model 5011, ESA Analytical, Aylesbury, UK) attached to
a Coulochem II electrochemical detector (ESA Analytical,
Aylesbury, UK) with electrode one set at −0.20 mV and
electrode two set at +0.34 mV with respect to the palladium
reference electrode online with a dedicated PC-based data
analysis programme (Chromeleon, Dionex, Camberley, UK).
A set of standards for each monoamine and their metabolite
were analysed after every fifth brain sample. Striata from
both control and mGluR agonist-treated groups were anal-
ysed on the same day.
2.12. Statistical Analysis of Data. Data from vehicle and drug-
treated groups were compared using two-tailed Student’s t-
test in Prism v5.0 software (GraphPad software, San Diego,
CA, USA). All data are presented as mean± standard error of
the mean (s.e.m) and diﬀerences were considered statistically
significant at P < .05.
3. Results
3.1. Delayed Intranigral Injection of 2R,4R-APDC Provides
Robust Neuroprotection against 6-OHDA Toxicity. The mean
number of TH+ cells in the unlesioned hemisphere of
drug or vehicle-treated animals was comparable and not
significantly diﬀerent. Intranigral injection of 6-OHDA
(12 μg) resulted in a ∼70% reduction (68.75 ± 1.71 [95%
CI: 64.89%–74.62%] of TH+ cells in the ipsilateral SNc of
vehicle-injected-animals (n = 8) relative to the contralateral
hemisphere; Figure 1(a)). By contrast, in animals receiving
intranigral injections of 2R,4R-APDC (10 nmol) for 7 days,
starting 48 hours post lesion, there was a significantly smaller
reduction in TH+ cells in the lesioned SNc compared to
vehicle treated animals (40.26 ± 3.18% [95% CI: 32.74%–
47.78%] versus 68.75 ± 1.71% [95% CI: 64.89%–74.62%];
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P < .001; Figure 1(a)). To control for possible alterations
in TH expression within atrophic neurons influencing the
observed eﬀects on TH+ cell number in the SNc, additional
cell counts were performed in the same animals from each
treatment group on tissue sections stained with the specific
neuronal marker, NeuN. Critically, the loss of TH+ cells
in the SNc was mirrored by an equivalent reduction in
NeuN+ cells in the lesioned SNc in vehicle-treated animals
(67.43 ± 1.15% [95% CI: 64.74%–69.95%]). By contrast, a
significantly smaller reduction in NeuN+ cells was observed
in 2R,4R-APDC-treated animals compared to vehicle-treated
animals (37.89 ± 4.03% [95% CI: 28.36%–47.42%] versus
(67.43 ± 1.15% [95% CI: 64.74%–69.95%]; P < .001;
Figure 1(b)), consistent with the observed preservation of
TH+ cells in the lesioned SNc. These data are illustrated in
representative photomicrographs of nigral TH+ and NeuN+
cells from both groups in Figures 1(c)–1(f).
No significant changes in monoamine content or
turnover were observed in sham-lesioned animals (Table 1).
Biochemical analysis of monoamine levels in the corpus
striatum in each treatment group demonstrated that the
neuroprotective eﬀects of delayed 2R,4R-APDC treatment
observed at the cellular level were associated with moderate,
but statistically significant preservation of DA, DOPAC,
and HVA concentrations in the ipsilateral corpus striatum
compared to vehicle-injected controls (P < .05; Table 1).
Importantly, no significant diﬀerences were observed for any
monoamine concentration in the contralateral hemisphere
between vehicle and drug-treated animals (P > .05; Table 1).
A significant increase in striatal dopamine turnover ratio was
observed in the lesioned striata of vehicle treated animals
(P < .05; Table 2), indicative of increased DA metabolism as
an intrinsic compensatory response to the 6-OHDA lesion.
Interestingly, in 2R,4R-APDC-injected animals, striatal DA
turnover remained elevated in the lesioned hemisphere
relative to the unlesioned side (P < .05; Table 2), but
importantly, this was significantly lower than that observed
in the lesioned striatum of vehicle-treated animals (P < .05;
Table 2).
3.2. Functional Recovery of Motor Behavior In Vivo Fol-
lowing Delayed Intranigral Injection of 2R,4R-APDC. To
functionally assess the neuroprotective eﬀect of delayed
intranigral 2R,4R-APDC injection (10 nmol), spontaneous
motor performance was assessed by observing forelimb use
during exploratory rearing behaviour in the cylinder test.
No significant forelimb use asymmetry was detected between
treatment groups prior to 6-OHDA lesioning (data not
shown). Both 2R,4R-APDC and vehicle-treated 6-OHDA
lesioned animals displayed a significant shift towards use of
the ipsilateral forelimb relative to the contralateral forelimb.
However, this ipsilateral forelimb use bias was moderately,
but significantly reduced in 2R,4R-APDC-injected animals
compared to vehicle-treated animals (42.6 ± 4.1% [95% CI:
32.79%–52.41%] versus 66.4± 5.9% [95% CI: 52.78–80.07];
P < .05; Figure 2(a)). In addition, the ipsilateral rotational
responses to (+)-amphetamine were also investigated just
prior to sacrifice. Injection of 5 mg/kg (+)-amphetamine
(i.p.) evoked a significant increase in net ipsilateral turns
over the 60-minute recording session in vehicle-treated 6-
OHDA lesioned animals (Figure 3(b)), which was markedly
attenuated in animals receiving delayed intranigral 2R,4R-
APDC (P < .001; Figure 2(b)).
3.3. Eﬀect of Delayed Treatment with 2R,4R-APDC on
Expression of Astroglial and Microglial Markers in the Sub-
stantia Nigra Pars Compacta. In vehicle-treated animals,
dopaminergic neuronal death induced by 6-OHDA lesioning
was accompanied by significant neuroinflammation. Indeed,
compared to the intact unlesioned hemisphere (Figure 3(a))
a marked increase in the intensity of both GFAP and
OX-42-immunostaining was observed in the lesioned SNc
relative to the unlesioned hemisphere (Figure 3(b)). Both
GFAP- and OX-42-positive (GFAP+/OX42+) cells in the
unlesioned hemisphere displayed morphology typical of
resting or quiescent cells (insets, Figures 3(a) and 3(e)). By
contrast, in the lesioned hemisphere, a marked increased
in GFAP+ and OX42+ cells displaying morphology typical
of activated cells was observed, with astrocytes displaying
thickened processes and a switch from ramified to ameboid
morphology in microglia (insets, Figures 3(b) and 3(f)).
Qualitative analysis suggests that delayed treatment with
2R,4R-APDC reduced the intensity of GFAP staining in
the lesioned SNc, (Figures 3(c) and 3(d)) compared to
vehicle-treated 6-OHDA lesioned animals (Figures 3(a) and
3(b)). In addition, fewer GFAP+ cells displayed activated
morphology in the lesioned SNc of 2R,4R-APDC-treated
animals compared to vehicle treated 6-OHDA lesioned
animals (Figures 3(a)–3(d)). In addition, a clear decrease in
the intensity of OX42+ staining in the lesioned SNc could
be observed in 2R,4R-APDC injected animals (Figures 3(g)
and 3(h)), compared to vehicle-treated 6-OHDA lesioned
animals (Figures 3(e) and 3(f)). Notably, qualitative analysis
suggested a marked decrease in OX42+ cells displaying
reactive morphology compared to vehicle-treated animals,
although this was not completely abrogated (Figures 3(e) and
3(h)). Consistent with these observations, a clear increase in
OX6+ cells displaying reactive morphology was also observed
in the lesioned SNc of vehicle-treated 6-OHDA lesioned ani-
mals compared to the unlesioned hemisphere (Figures 4(a)
and 4(b)), confirming the presence of activated microglia.
Importantly, this was markedly, but not completely reduced
in animals injected with 2R,4R-APDC (Figures 4(c) and
4(d)).
4. Discussion
In the current study we have extended our initial preliminary
observations [19] in vivo using the dual mGluR2/3 agonist
2R,4R-APDC in a rodent partial lesion 6-OHDA model
of PD. Indeed, we now report that delayed (48 hour post
lesion) subchronic intranigral administration of 2R,4R-
APDC (10 nmol) protects the rodent nigrostriatal system
against 6-OHDA toxicity at the cellular (preservation of
nigral TH+ cell bodies) and biochemical level (preservation
of striatal monoamine concentrations). This is eﬀectively
translated into functional recovery as demonstrated by
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Figure 1: Delayed (48 hours post lesion) subchronic intranigral administration of 2R,4R-APDC (10 nmol in 4 μL) attenuates 6-OHDA
toxicity in vivo. Scatter plots showing (a) the mean percentage loss ± s.e.m of nigral TH+ cells and (b) NeuN+ cells in each treatment group
(Vehicle n = 10, 2R,4R-APDC, n = 8). Note that 6-OHDA induces an equivalent reduction of both TH and NeuN+ cells in the SNc, which
is significantly attenuated following delayed administration of 2R,4R-APDC (10 nmol). ∗∗∗P < .001, vehicle versus 2R,4R-APDC (2-tailed
students t-test). (c)–(f) Representative photomicrographs (×40) of DAB/peroxidase staining for TH and NeuN+ cells in the SNc from each
treatment group, also showing the ROI encompassing the SNc used for cell counting, scale bar 200 μm. (c) TH, 6-OHDA + vehicle, (d)
NeuN,6-OHDA + vehicle, (e) TH, 6-OHDA + 2R,4R-APDC, (f) NeuN, 6-OHDA + 2R,4R-APDC.
improved forelimb asymmetry scores and correction of
amphetamine-induced rotational asymmetry. In addition,
these eﬀects were associated with a qualitative decrease in
microglial activation in the SNc. Importantly, in animals
receiving 2R,4R-APDC post lesion, NeuN+ and TH+ cell
loss was attenuated in parallel in the ipsilateral SNc, strongly
supporting a neuroprotective eﬀect, rather than alterations
in TH expression in atrophic neurones. However, although
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Table 1: Mean striatal concentrations of dopamine (DA), dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) as measured
by HPLC-ECD in the unlesioned and lesioned striata in each treatment group. Data shown are mean ng/mg wet weight tissue ± s.e.m.
∗P < .05, ∗∗P < .01 unlesioned versus lesioned hemisphere, †P < .05, ††P < .01 2R,4R-APDC versus vehicle-treated animals [10]. Drug
concentration in nmol (final injection volume 4 μL).
Treatment
group
[DA] Unlesioned
ng/mL
[DA] Lesioned
ng/mL
[DOPAC] Unlesioned
ng/mL
[DOPAC] Lesioned
ng/mL
[HVA] Unlesioned
ng/mL
[HVA] Lesioned
ng/mL
Vehicle 7.26 ± 0.16 1.042 ± 0.23∗∗ 1.99 ± 0.13 0.59 ± 0.15∗∗ 0.74 ± 0.07 0.33 ± 0.09∗∗
2R,4R-APDC 7.87 ± 0.18 3.40 ± 0.54∗∗†† 1.46 ± 0.10 0.81 ± 0.07∗∗† 0.65 ± 0.04 0.45 ± 0.06∗∗†
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Figure 2: Neuroprotection against 6-OHDA toxicity following delayed subchronic intranigral administration of 2R,4R-APDC (10 nmol in
4 μL) translates into functional recovery of motor deficits. (a) Bar graph of mean percentage forelimb use asymmetry ± s.e.m in vehicle
and 2R,4R-APDC (10 nmol)-treated animals, ∗∗P < 0.01, vehicle versus 2R,4R-APDC. (b) Bar graph of amphetamine-induced rotational
behavior, expressed as net ipsilateral turns over 60 minutes ± s.e.m in vehicle and 2R,4R-APDC-treated animals, ∗∗∗P < .001, vehicle versus
2R,4R-APDC.
Table 2: Measurement of striatal dopamine metabolism in the
unlesioned and lesioned striata in each treatment group. Data are
expressed as mean dopamine turnover ratio ± s.e.m calculated by
the expression (DOPAC + HVA/DA) using mean pmol/mg wet
weight tissue values for DA, DOPAC, and HVA, respectively. ∗P <
.05, unlesioned versus lesioned hemisphere. †P < .05, 2R,4R-APDC
versus vehicle-treated animal [10]. Drug concentrations in nmol
(final injection volume 4 μL).
Treatment
group
DA turnover ratio
Unlesioned
DA turnover ratio
lesioned
Vehicle 0.30 ± 0.04 0.45 ± 0.12∗
2R,4R-APDC 0.26 ± 0.10 0.31 ± 0.04∗†
intranigral treatment with 2R,4R-APDC lowered the intrin-
sic compensatory increases in striatal DA metabolism com-
pared to vehicle-treated animals, this was not completely
reversed. Thus, we cannot exclude the possibility that the
neuroprotective eﬀects of 2R,4R-APDC on striatal DA and
its metabolites is not partly due to intrinsic compensatory
mechanisms. Furthermore, it will be important in future
studies to determine whether these data are replicated upon
systemic administration and in a more progressive model of
PD, such as the intrastriatal 6-OHDA model [33]. Notably,
2R,4R-APDC did not completely prevent 6-OHDA toxicity
in vivo, consistent with previous in vivo studies [14, 17–19].
Preliminary data from our laboratory have shown the
neuroprotective eﬀects of 2R,4R-APDC are abrogated by
coadministration with EGLU, a highly selective group II
mGluR antagonist [34]. These observations strongly sug-
gesting the beneficial eﬀects of 2R,4R-APDC eﬀects are
mediated through selective activation of mGluR2/3 in vivo
(Vernon et al., unpublished observations). Interestingly, the
relatively weak neuroprotective eﬀects observed in previous
studies [14, 17–19] may be explained by evidence suggesting
that mGlu2 and 3 receptors have divergent functions in
vivo [15]. Indeed, in an elegant knock-out mice study,
Corti and colleagues (2007) demonstrated that the systemic
administration of the dual mGluR2/3 agonist LY379268
protected striatal neurons against NMDA toxicity in wild-
type and mGluR2−/− mice but not in mGluR3−/− mice [15].
Moreover, LY379268 was neuroprotective against nigros-
triatal degeneration induced by low doses of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mGluR2−/−
mice, strongly suggesting that these in vivo neuroprotective
eﬀects are dependent on the activation of mGluR3 [15].
Since LY379268 was only neuroprotective in mGlu2−/− mice,
these data suggest that activation of mGluR2 in wild-type
mice may counterbalance the protective activity of the drug
[15]. This hypothesis is supported by detailed in vitro
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Figure 3: Neuroprotection against 6-OHDA toxicity following delayed subchronic intranigral administration of 2R,4R-APDC is associated
with qualitative reductions in inflammatory markers. Representative photomicrographs (×40) of DAB/peroxidase staining for GFAP
(astrocytosis) and OX-42 (microgliosis) in the SNc from each treatment group (scale bar 200 μm.). Panels (a)–(g) show the intensity and
distribution of GFAP+ and OX-42+ cells in the contralateral control SN of vehicle (a), (c) and (e), (g) 2R,4R-APDC (10 nmol)-injected
animals. Panels (b)–(h) show the intensity and distribution of GFAP+ and OX-42+ cells in the Lesioned SNc of vehicle (b), (d) and (e),
(g) 2R,4R-APDC (10 nmol)-injected animals. (Insets (a)–(h)), ×60, enlargements of outlined areas (scale bar 10 μm)). Note the apparent
reduction in intensity of GFAP+ and OX-42+ staining in 2R,4R-APDC-injected animals compared to vehicle-treated animals. Further,
2R,4R-APDC treatment appeared to reduce the number of cells with morphology characteristic for reactive astrocytes or activated microglia
in the SNc in comparison to vehicle-treated controls.
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Figure 4: Neuroprotection against 6-OHDA toxicity following delayed subchronic intranigral administration of 2R,4R-APDC is associated
with reduced numbers of activated microglia in the SNc. Representative photomicrographs (×40) of DAB/peroxidase staining for OX-6,
a marker of activated microglia in the SNc from each treatment group (scale bar 200 μm.). (a) 6-OHDA + vehicle, unlesioned SNc, (b)
6-OHDA + vehicle, lesioned SNc, (c) 6-OHDA + 2R,4R-APDC (10 nmol) unlesioned SNc, (d) 6-OHDA + 2R,4R-APDC (10 nmol) lesioned
SNc. Note the increase in intensity of OX-6 staining and the increase in OX-6+ cells displaying morphology of activated microglia in the
lesioned SNc of vehicle-treated animal, which appears markedly reduced in animals treated with 2R,4R-APDC.
experiments in the same study, which provided evidence
that activation of mGluR2 may enhance NMDA toxicity
in mixed cortical cultures [15]. Thus, in vitro and in vivo
evidence converges to suggest that mGluR3 mediates the
neuroprotective activity of mGluR2/3 receptor agonists in
vivo and that a combined activation of mGluR2 and mGluR3
receptors may therefore limit the extent of neuroprotection
observed [15]. Conversely, it is interesting to note that
mGluR2 activation alone is required for novel antipsychotic
actions of dual mGluR2/3 agonists in vivo [35, 36]. However,
it is clear that dual mGluR2/3 agonists such as LY367385
and indeed, 2R,4R-APDC might be predicted to have less
neuroprotective eﬃcacy than mGluR3 agonists alone [15].
This also has implications for the potential antiparkin-
sonian eﬀects of these compounds in preclinical models of
PD. In the current study, we provide preliminary evidence
that neuroprotection following delayed, subchronic intran-
igral administration of 2R,4R-APDC translated into func-
tional recovery, confirming a neuroprotective eﬀect at the
behavioural level. These data are somewhat consistent with
previous data in which systemic administration of the dual
mGluR2/3 agonist LY379268 weakly ameliorated reserpine-
induced akinesia, but did not reverse amphetamine rota-
tional asymmetry in 6-OHDA lesioned rats, despite mod-
est neuroprotective eﬀects [18]. Interestingly, intrastriatal
injection of 2R,4R-APDC did not reverse haloperidol-
induced catalepsy or muscle rigidity in rats [21]. These
divergent results may be explained by data demonstrating
that dual mGluR2/3 agonists, (including LY379268 and
2R,4R-APDC) inhibit not only glutamate, but also DA
release in the striatum in vivo [37]. Interestingly, LY379268
also displays partial agonist activity at DA D2 receptors
in vitro and in vivo [38, 39]. Thus, following systemic or
intrastriatal administration, dual mGluR2/3 agonists may
bind to presynaptic DA D2 receptors thereby decreasing DA
release in the striatum and inhibiting locomtion [38, 39].
Whether 2R,4R-APDC has partial agonist activity at DA
D2 receptors is unknown. However, recent data suggest
that Group II mGluR, in particular mGluR2, are closely
associated with DA D2 receptors and may regulate their
number and activity in the striatum [40, 41]. Indeed, the
number of D2 receptors in the striatum is markedly elevated
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in mGluR2 and mGluR3 knock-out mice [40, 41]. Moreover,
in vitro striatal homogenates from mGluR2 knock-out mice
displayed significantly greater supersensitivity responses to
the D2 receptor agonist (+)PHNO when compared to those
from mGluR3 knock-outs, suggesting that mGluR2 and DA
D2 receptors are functionally linked in vivo [40].
Taken together, these data suggest that translation of
neuroprotection into functional recovery following dual
mGluR2/3 agonist treatment is critically dependent on
the route of drug administration. Indeed, our own data
demonstrate that this may be observed following activation
of nigral mGluR2/3 in isolation. By contrast, following
systemic administration, confounding actions in other brain
regions particularly, but not exclusively, in the striatum
might occlude this eﬀect [18]. Notably again, this appears
predominantly due to the activation of mGluR2 [38]. Thus,
these data reinforce the prediction that mGluR3 selective
compounds may be more eﬃcacious as both neuroprotective
and antiparkinsonian agents, although this remains to be
tested in vivo.
In the current study we also observed that the neu-
roprotective eﬀects of 2R,4R-APDC were associated with
a qualitative decrease in microglial markers in the SNc.
Interestingly, in vitro, activation of mGluR3 expressed in
microglia inhibits microglial activation and secretion of
neurotoxic cytokines [42, 43]. Conversely, activation of
microglial mGluR2 enhances microglial toxicity in vitro [42,
43]. Again, these data are consistent with divergent roles of
mGluR2 and 3 in vivo [15] and may certainly also contribute
to the modest neuroprotective eﬀects of 2R,4R-APDC in vivo
by counterbalancing beneficial eﬀects of mGluR3 activation.
Nevertheless, based on this observation it is tempting to
speculate that the neuroprotective eﬀects of 2R,4R-APDC
and other dual mGluR2/3 agonists in vivo may involve
antiinflammatory mechanisms, including prevention of toxic
microglial activation, alongside documented eﬀects such as
promoting secretion of trophic-factors from astrocytes [12–
15]. However, these data should be interpreted cautiously,
as decreases in microglial markers may simply reflect a
secondary eﬀects due to neuroprotection by 2R,4R-APDC
through alternative mechanisms. Nevertheless, these initial
observations suggest that further studies on the eﬀects of
mGluR2/3 agonists on microglial response in vivo may be
warranted.
5. Conclusions
In conclusion, this study extends our preliminary findings
[19] and provides evidence that subchronic intranigral injec-
tion of the dual mGluR2/3 agonist 2R,4R-APDC robustly
attenuates dopaminergic neurodegeneration in vivo, even
when treatment initiation is delayed. Furthermore, this
translates into modest functional recovery, at least following
intranigral administration in vivo. Moreover, the neuropro-
tective eﬀects of 2R,4R-APDC may involve modification of
the inflammatory response as evidenced by a qualitative
reduction on the expression of microglial markers in the
SNc. However, we fully acknowledge that the significance of
these data should be interpreted with the caveat that we have
utilised a dual mGluR2/3 agonists and thus any beneficial
eﬀects are likely to be influenced by confounding eﬀects
due to activation of mGluR2 in vivo [15]. Nevertheless,
these data provide further evidence for the rationale of
targeting Group II mGluR in PD, although it will be vitally
important in future studies to repeat these experiments using
mGluR3-selective compounds as these become available.
Overall, this also has implications for the clinical use of dual
mGluR2/3 agonists for the treatment of neurodegenerative
diseases. Indeed, on the basis of currently available data
from pre-clinical studies, orthosteric nonselective mGluR2/3
agonists may be of limited clinical use as neuroprotec-
tive/antiparkinsonian agents due to confounding eﬀects at
mGluR2 in vivo [15]. The development of a novel class
of compounds, known as positive allosteric modulators
(PAMs), which do not activate the receptor directly, but
bind to a site distinct from the glutamate-binding site, with
the eﬀect of increasing the response of the receptor to
endogenous glutamatergic tone, may oﬀer a solution to this
problem, since such binding sites are often less constrained
and more amenable to discovery of novel, subtype-selective
compounds, compared to targeting the glutamate binding
site [44]. Indeed, a number of PAMs selective for mGluR2
have been developed, which may oﬀer an exciting alternative
approach to dual mGluR2/3 agonists at least for their
antipsychotic or anxiolytic indications [44–47]. Notably
however, this has not been matched by a similar develop-
ment of mGluR3 selective PAMs. Thus the development of
mGluR3 selective compounds is eagerly awaited and could
represent a crucial step towards the potential use of these
compounds for use in neurodegenerative conditions such as
PD.
Nonstandard Abbreviations
2R,4R-APDC: 2R,4R-4-aminopyrrolidine-2,4-
dicarboxylate
EGLU: (S)-α-Ethylglutamic acid
DCG-IV: (2S,2′R,3′R)-2-(2′,3′-
Dicarboxycyclopropyl)glycine
HPLC-ECD: high performance liquid chromatography-
electrochemical detection
LY379268: (1R,4R,5S,6R)-4-Amino-2-
oxabicyclo[3.1.0]hexane-4,6-dicarboxylic
acid
LY354740: (1S,2S,5R,6S)-2-
aminobicyclo[3.1.0]hexane-2,6-dicarboxylic
acid
6-OHDA: 6-hydroxydopamine; mGluR, metabotropic
glutamate receptor
MTN: medial terminal nucleus
NMDAR: N-methyl-D-aspartate receptor
PD: Parkinson’s disease
+PHNO: 4-propyl-9-hydroxynaphthoxazine
SNc: substantia nigra pars compacta
SNr: substantia nigra pars reticulata
STN: subthalamic nucleus
VTA: ventral tegmental area.
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